The approval of a new drug by a regulatory authority such as Health Canada typically leads to positive market perception and can open up new revenue streams for pharmaceutical companies. For Pfizer, this approval is likely to enhance its product portfolio in Canada, potentially leading to increased sales and a stronger market position. The direct mention of Pfizer Canada and the significance of the Notice of Compliance for Velsipity suggest a high relevance and importance of this news for Pfizer's stock.